Comparison of JAK2 V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis

(2015) F Palandri et al.   LEUKEMIA

Masked polycythemia Vera (mPV): Results of an international study

(2013) Tiziano Barbui et al.   AMERICAN JOURNAL OF HEMATOLOGY

Masked polycythemia vera diagnosed according to WHO and BCSH classification

(2013) Tiziano Barbui et al.   AMERICAN JOURNAL OF HEMATOLOGY

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon  -2a

(2013) A. Quintas-Cardama et al.   BLOOD

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

(2013) J V Jovanovic et al.   LEUKEMIA

Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis

(2012) T. Barbui et al.   BLOOD

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)

(2012) T. Barbui et al.   BLOOD

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis

(2012) Grzegorz Helbig et al.   MEDICAL ONCOLOGY

The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis

(2012) Umberto Gianelli et al.   MODERN PATHOLOGY

Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

(2012) Roberto Marchioli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study

(2011) Francesca Palandri et al.   ANNALS OF HEMATOLOGY

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

(2010) F Passamonti et al.   LEUKEMIA

Long-term follow-up of 386 consecutive patients with essential thrombocythemia: Safety of cytoreductive therapy

(2009) Francesca Palandri et al.   AMERICAN JOURNAL OF HEMATOLOGY

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Reply to J. Thiele et al

(2009) Peter J. Campbell et al.   JOURNAL OF CLINICAL ONCOLOGY

JAK2V617Fmutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients

(2009) Francesca Palandri et al.   LEUKEMIA & LYMPHOMA

Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review

(2009) Federico Lussana et al.   THROMBOSIS RESEARCH

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

(2008) V. De Stefano et al.   HAEMATOLOGICA

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

(2008) E. Antonioli et al.   HAEMATOLOGICA